Zometa News and Research

RSS
Zometa is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronate and zoledronic acid.
Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates

FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates

Amgen to present oncology portfolio results at ESMO Congress

Amgen to present oncology portfolio results at ESMO Congress

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

Amgen granted FDA priority review designation for denosumab BLA

Amgen granted FDA priority review designation for denosumab BLA

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Positive results from new analyses of denosumab Phase 3 trials

Positive results from new analyses of denosumab Phase 3 trials

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Cancer pain drug market to be $3.7 billion in 2018

Cancer pain drug market to be $3.7 billion in 2018

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen to present its four Phase 3 clinical trial results

Amgen to present its four Phase 3 clinical trial results

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

Effectiveness and risks of six bisphosphonates for osteoporosis

Effectiveness and risks of six bisphosphonates for osteoporosis

Loyola to study for first time IV medication for osteopenia and inflammatory bowel diseases

Loyola to study for first time IV medication for osteopenia and inflammatory bowel diseases